FeesSafety
Pluang+

Fortrea raises 2026 revenue and EBITDA guidance after Q3 shows profit and strong cash flow

Company Fundamentals
29 Oct 2026, 13:30 WIB
GlobeNewsWire
View Source
Bullish
Fortrea raises 2026 revenue and EBITDA guidance after Q3 shows profit and strong cash flow

Fortrea Holdings reported Q3 2026 revenue of $691.5 million and a GAAP net income of $0.6 million, a significant improvement from a net loss last year. Adjusted EBITDA rose to $58 million, supported by strong operational execution and margin improvement. The company raised its full-year 2026 revenue guidance to $2.665-$2.690 billion and adjusted EBITDA guidance to $210-$218 million, reflecting confidence in sustained growth and cash flow generation. Fortrea continues investing in early clinical development and technology to enhance its competitive position in the contract research organization market.

Fortrea's Q3 2026 results provide context for readers interested in health-sector dynamics. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 29, 2026 17:11 WIB: Among 150 priced US health-sector stocks, 86 rose and 57 fell today. Butterfly Network Inc. (BFLY) gained 6.53% to USD 8.32 with a typical hold time of 14 days, outperforming Nuwellis Inc. (NUWE) which rose 5.48% to USD 5.87 despite a 74% sell order activity and a longer typical hold time of 29 days. ClearPoint Neuro Inc. (CLPT) increased 4.17% to USD 11.00 with balanced buy and sell orders and a shorter hold time of 11 days.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App